Pear Therapeutics (PEAR)

Company Profile

Pear Therapeutics, is the parent company of Pear Therapeutics (US), Inc. Pear is the leader in developing and commercializing software-based medicines, called prescription digital therapeutics (PDTs). Pear aims to redefine care through the widespread use of clinically validated software-based therapeutics to provide better outcomes for patients, smarter engagement and tracking tools for clinicians, and cost-effective solutions for payers. Pear has the first end-to-end platform to discover, develop, and deliver PDTs to patients and a pipeline of products and product candidates across therapeutic areas, including the first three PDTs with disease treatment claims from the FDA. Pear’s product, reSET®, for the treatment of substance use disorder, was the first PDT to receive marketing authorization from the FDA to treat disease. Pear’s second product, reSET-O®, for the treatment of opioid use disorder, was the first PDT to receive Breakthrough Designation. Pear’s third product, Somryst® for the treatment of chronic insomnia, was the first PDT submitted through FDA’s traditional 510(k) pathway while simultaneously reviewed through FDA’s Software Precertification Pilot Program.

Company profile

Ticker

PEAR, PEARW

Exchange

Website

Incorporated

Location

Fiscal year end

Sector

Professional, Scientific, and Technical Services > Research and Development in the Physical, Engineering, and Life Sciences (except Biotechnology)

Industry (SIC)

Services - Health Services

LifeStance Health • InnovAge Holding • Sharecare • Oak Street Health • CRH Medical • GeneDx • UpHealth • U.S. Physical Therapy • Digital Health Acquisition • DocGo ...

Former names

Thimble Point Acquisition Corp.

SEC CIK

0001835567

Corporate docs

Articles of Incorporation & Bylaws

Underwriting Agreements

Plans of Reorganization

Indentures

Material Contracts & Credit Agreements

Subsidiaries Lists

IRS number

854103092

PEAR stock data

1M 1Y 5Y

Analyst ratings and price targets

Last 3 months

Average target

$6.67

Low target

$5.00

High target

$8.00

Latest filings (excl ownership)

View all

EFFECT

Notice of effectiveness

12 Jan 23

424B5

Prospectus supplement for primary offering

10 Jan 23

424B3

Prospectus supplement

4 Jan 23

EFFECT

Notice of effectiveness

4 Jan 23

POS AM

Prospectus update (post-effective amendment)

3 Jan 23

424B3

Prospectus supplement

3 Jan 23

8-K

Entry into a Material Definitive Agreement

Prospectus supplement

14 Nov 22

Transcripts

PEAR

Earnings call transcript

2022 Q3

15 Nov 22

PEAR

Earnings call transcript

2022 Q2

14 Aug 22

PEAR

Earnings call transcript

2022 Q1

17 May 22

PEAR

Earnings call transcript

2021 Q4

29 Mar 22

Latest ownership filings

View all

CHRISTOPHERD T GUIFFRE

Financial summary

Financial statements Chart PEAR financial data

Quarter (USD)	Sep 22	Jun 22	Mar 22	Dec 21
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Annual (USD)	Dec 21
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Cash burn rate (est.)	Burn method: Change in cash		Burn method: Operating income		Burn method: FCF (opex + capex)
	Last Q	Avg 4Q	Last Q	Avg 4Q	Last Q	Avg 4Q
Cash on hand (at last report)	60.17 mm	60.17 mm	60.17 mm	60.17 mm	60.17 mm	60.17 mm
Cash burn (monthly)	164.00 k	285.75 k	8.88 mm	10.70 mm	(no burn)	6.38 mm
Cash used (since last report)	708.67 k	1.23 mm	38.36 mm	46.25 mm	n/a	27.56 mm
Cash remaining	59.46 mm	58.94 mm	21.81 mm	13.92 mm	n/a	32.61 mm
Runway (months of cash)	362.6	206.2	2.5	1.3	n/a	5.1

Beta Read what these cash burn values mean

Financial data from company earnings reports.

Institutional ownership, Q3 2022

PEAR institutional ownership history Ownership history

37.3% owned by funds/institutions

13F holders	Current	Prev Q	Change
Total holders	41	78	-47.4%
Opened positions	2	13	-84.6%
Closed positions	39	19	+105.3%
Increased positions	4	12	-66.7%
Reduced positions	8	12	-33.3%

13F shares	Current	Prev Q	Change
Total value	351.67 mm	562.18 mm	-37.4%
Total shares	51.90 mm	129.08 mm	-59.8%
Total puts	0.00	0.00
Total calls	773.33 k	1.11 mm	-30.6%
Total put/call ratio	–	–	–

Largest owners	Shares	Value	Change
5AM Ventures IV	13.53 mm	$26.12 mm	-11.3%
LJ10	11.55 mm	$107.45 mm	0.0%
Arboretum Ventures IV	10.86 mm	$100.99 mm	0.0%
JAZZ Human Performance Opportunity Fund	9.68 mm	$90.04 mm	0.0%
LMR Partners	2.44 mm	$4.98 mm	+25.8%
Walleye Capital	767.39 k	$130.00 k	+4201.3%
Owl Creek Asset Management	414.00 k	$70.00 k	0.0%
Q Global Advisors	250.00 k	$45.00 k	NEW
BLK Blackrock	236.70 k	$40.00 k	-64.4%
Advisory Research	207.89 k	$35.00 k	-2.7%

Largest transactions	Shares	Bought/sold	Change
Temasek	0.00	-26.80 mm	EXIT
5AM Venture Management	0.00	-18.63 mm	EXIT
SB Global Advisors	0.00	-12.10 mm	EXIT
Arboretum Ventures	0.00	-10.86 mm	EXIT
TB Alternative Assets	0.00	-2.07 mm	EXIT
5AM Ventures IV	13.53 mm	-1.73 mm	-11.3%
Vanguard	0.00	-1.06 mm	EXIT
PLTR Palantir	0.00	-1.00 mm	EXIT
Perceptive Advisors	0.00	-900.55 k	EXIT
Walleye Capital	767.39 k	+749.55 k	+4201.3%

Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

Recent insider trades

PEAR insider ownership history Insider history

Date	Owner	Security	Transaction	Code	Indirect	10b5-1	$Price	#Shares	$Value	#Remaining
20 Jan 23	Katherine Jeffery	Class A Common Stock	Sell	Dispose S	No	No	1.13	7,096	8.02 k	8,304
20 Jan 23	Yuri Maricich	Class A Common Stock	Sell	Dispose S	No	No	1.13	12,162	13.74 k	94,333
20 Jan 23	Corey McCann	Class A Common Stock	Sell	Dispose S	No	No	1.13	34,731	39.25 k	8,210,834
20 Jan 23	Erin K. Brenner	Class A Common Stock	Sell	Dispose S	No	No	1.13	8,690	9.82 k	43,310
20 Jan 23	Christopherd T Guiffre	Class A Common Stock	Sell	Dispose S	No	No	1.13	19,540	22.08 k	29,960